Earnings ·
Kura Oncology, Inc. reported second quarter 2026 financial results on August 12, 2026
KURAKura Oncology, Inc.
Kura Oncology, Inc. reported second quarter 2026 financial results on August 12, 2026. Net product revenue from KOMZIFTI (ziftomenib) reached $9.1 million, a 57% increase from the first quarter, driven by approximately 115 new patient starts and over 250 total prescriptions. The company reported a net loss of $68.3 million compared to $66.1 million in the prior year period. As of June 30, 2026, Kura held $519.0 million in cash, cash equivalents, and short-term investments, supplemented by $180 million in anticipated collaboration payments from Kyowa Kirin. The company provided clinical updates on ziftomenib's frontline AML potential and darlifarnib's activity in solid tumors. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer.